Evidence map›Paper›PMID 33436622›Full record

ArticleNature communications2021

Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance.

Hai Wang, Yutong Liang, Yue Yin, Jie Zhang, Wen Su, Alisa M White, Bin Jiang, Jiangsheng Xu, Yuntian Zhang, Samantha Stewart and 2 more

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Regulation of Nucleotide Metabolism with Nutrient-Sensing Nanodrugs for Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Hai WangFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA. wanghai@nanoctr.cn.ORCID 0000-0002-1292-998X
Yutong LiangFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
Yue YinCAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, 100190, Beijing, China.
Jie ZhangCAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, 100190, Beijing, China.
Wen SuCAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, 100190, Beijing, China.
Alisa M WhiteFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
Bin JiangFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
Jiangsheng XuFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
Yuntian ZhangFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
Samantha StewartFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
Xiongbin LuDepartment of Medical and Molecular Genetics and Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.ORCID 0000-0002-7987-9825
Xiaoming HeFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA. shawnhe@umd.edu.ORCID 0000-0003-0125-6086
University of Maryland, College Park · USNational Center for Nanoscience and Technology · CNIndiana University Health · USUniversity of Maryland, Baltimore · US

Funding

Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancerR01CA243023 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HE, XIAOMING · 2020 to 2024
$2.0M
Nanotechnology enabled targeting of p53 deficiency in human cancerR01CA206366 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HE, XIAOMING, LU, XIONGBIN · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA206366NCI NIH HHS R01 CA243023
6 · The paper itself

Abstract

The transmembrane P-glycoprotein (P-gp) pumps that efflux drugs are a major mechanism of cancer drug resistance. They are also important in protecting normal tissue cells from poisonous xenobiotics and endogenous metabolites. Here, we report a fucoidan-decorated silica-carbon nano-onion (FSCNO) hybrid nanoparticle that targets tumor vasculature to specifically release P-gp inhibitor and anticancer drug into tumor cells. The tumor vasculature targeting capability of the nanoparticle is demonstrated using multiple models. Moreover, we reveal the superior light absorption property of nano-onion in the near infrared region (NIR), which enables triggered drug release from the nanoparticle at a low NIR power. The released inhibitor selectively binds to P-gp pumps and disables their function, which improves the bioavailability of anticancer drug inside the cells. Furthermore, free P-gp inhibitor significantly increases the systemic toxicity of a chemotherapy drug, which can be resolved by delivering them with FSCNO nanoparticles in combination with a short low-power NIR laser irradiation.

Indexed as

Drug Delivery SystemsDrug Resistance, NeoplasmAnimalsATP Binding Cassette Transporter, Subfamily B, Member 1CarbonCell DeathCell Line, TumorCell ProliferationDoxorubicinHumansHuman Umbilical Vein Endothelial CellsMiceMicrofluidicsNanoparticlesNeoplasmsPhotothermal TherapyATP Binding Cassette Transporter, Subfamily B, Member 1CarbonDoxorubicinfucoidanPolysaccharidesP-SelectinSilicon Dioxide

Identifiers

PMID33436622
PMCPMC7803730
OpenAlexW3119775908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.